Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.

Saved in:
Bibliographic Details
Title: Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.
Authors: Aredo JV; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Wakelee HA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Ramchandran KJ; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Neal JW; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Diehn M; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Hui AB; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Salahudeen A; Department of Internal Medicine, University of Illinois Cancer Center, Chicago, Illinois., Kwong B; Department of Dermatology, Stanford University School of Medicine, Stanford, California., Berry GJ; Department of Pathology, Stanford University School of Medicine, Stanford, California., Guo HH; Department of Radiology, Stanford University School of Medicine, Stanford, California., Cunanan K; Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California., Vali S; Cellworks Group, South San Francisco, California (Prior)., Pancirer D; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Tsang V; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Hwang G; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Loza M; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Johnson B; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Blanchard I; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Padda SK; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Hematology/Oncology, Fox Chase Cancer Center/Temple Health, Philadelphia, Pennsylvania.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2024 Oct 17; Vol. 5 (12), pp. 100741. Date of Electronic Publication: 2024 Oct 17 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3643
DOI:10.1016/j.jtocrr.2024.100741